Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| INDP | SC 13D/A | neutral | 4/10 | Sino Lion Ventures Ltd and Chenhao Xu filed Amendment No. 3 to their Schedule 13D, reporting a decrease in beneficial ow | Oct 22, 2026 |
| VRTX | 3 | neutral | 2/10 | Daniel J. Brennan filed a Form 3 initial statement of beneficial ownership with the SEC, indicating he has become a repo | Oct 22, 2026 |
| RCUS | 424B5 | bearish | 6/10 | Arcus Biosciences priced a $250M underwritten public offering of 14,285,715 common shares at $17.50 per share, an 8.4% d | Oct 22, 2026 |
| MRK | 3/A | neutral | 1/10 | David R. Maraldo, EVP & President of Merck's Human Health business, filed an amended Form 3/A to correct the number of s | Oct 22, 2026 |
| INDP | SC 13D/A | neutral | 3/10 | Junyi Dai, CEO and Chairman of Indaptus Therapeutics, filed Amendment No. 3 to Schedule 13D reporting a passive decrease | Oct 22, 2026 |
| IFRX | 6-K | neutral | 3/10 | InflaRx presented pre-clinical data on izicopan at Kidney Week 2026, showing statistically significant renal protection | Oct 22, 2026 |
| GNTA | 6-K | neutral | 4/10 | The Tribunal of Milan issued an interim order suspending the June 29, 2026 shareholder resolution that appointed a new B | Oct 22, 2026 |
| INDP | SC 13D/A | neutral | 4/10 | Yun Yao filed Amendment No. 3 to her Schedule 13D, reporting a decrease in her beneficial ownership percentage from a pr | Oct 22, 2026 |
| DYN | PRESS-RELEASE | neutral | 2/10 | Dyne Therapeutics granted inducement equity awards to 16 new hires, consisting of options for 290,100 shares and RSUs fo | Oct 22, 2026 |
| AARD | PRESS-RELEASE | bullish | 7/10 | FDA lifted the clinical hold on Aardvark's IND for ARD-101 in Prader-Willi Syndrome, allowing clinical development to re | Oct 22, 2026 |
| VOR | PRESS-RELEASE | bullish | 7/10 | Vor Bio announced final two-year Phase 3 TELIGAN results for telitacicept in IgA nephropathy, showing a statistically si | Oct 22, 2026 |
| ELUT | PRESS-RELEASE | neutral | 1/10 | Elutia Inc. announced it will report its Q3 2026 results on November 5, 2026. | Oct 22, 2026 |
| CRL | 144 | neutral | 2/10 | Director James C. Foster filed a Form 144 notice of intent to sell 24,042 shares of Charles River Laboratories common st | Oct 22, 2026 |
| IGC | DEFA14A | neutral | 2/10 | IGC Pharma, Inc. filed a DEFA14A (additional definitive proxy soliciting materials) on October 22, 2026. The filing is a | Oct 22, 2026 |
| GYRE | 8-K | neutral | 2/10 | Gyre Therapeutics entered into formal employment agreements with CEO Ying Luo and CFO Thomas Eastling on October 16, 202 | Oct 22, 2026 |
| ANIK | PRESS-RELEASE | neutral | 1/10 | Anika Therapeutics Inc. announced it will report its Q3 2026 results on November 6, 2026. | Oct 22, 2026 |
| KYMR | PRESS-RELEASE | neutral | 1/10 | Kymera Therapeutics, Inc. announced it will report its Q3 2026 results on October 29, 2026. | Oct 22, 2026 |
| DNLI | PRESS-RELEASE | neutral | 1/10 | Denali Therapeutics Inc. announced it will report its Q3 2026 results on November 3, 2026. | Oct 22, 2026 |
| KNSA | PRESS-RELEASE | neutral | 1/10 | Kiniksa Pharmaceuticals International, Plc announced it will report its Q3 2026 results on October 27, 2026. | Oct 22, 2026 |
| CTY | SC 13G | neutral | 3/10 | Invus Global Management, LLC and affiliated entities filed a Schedule 13G disclosing a passive 8.1% stake in City Therap | Oct 22, 2026 |
| IFRX | PRESS-RELEASE | neutral | 3/10 | InflaRx presented pre-clinical data at Kidney Week 2026 showing izicopan reduced renal injury markers in two hamster kid | Oct 22, 2026 |
| QGEN | SC TO-C | bullish | 8/10 | EQT Private Equity, alongside ADIA and CPP Investments, announced a recommended all-cash public takeover offer for QIAGE | Oct 22, 2026 |
| VERA | PRESS-RELEASE | bullish | 8/10 | Vera Therapeutics announced positive final efficacy results from the ORIGIN 3 trial of TRUTAKNA (atacicept-vymj) in IgA | Oct 22, 2026 |
| SPRC | PRESS-RELEASE | neutral | 4/10 | SciSparc subsidiary NeuroThera Labs announced completion of manufacturing and QP batch release certification for SCI-110 | Oct 22, 2026 |
| ERNA | PRESS-RELEASE | neutral | 3/10 | Ernexa Therapeutics released a Virtual Investor segment discussing its pre-IND interaction with the FDA for lead candida | Oct 22, 2026 |
| EPRX | 6-K | neutral | 2/10 | Eupraxia announced management participation in several upcoming investor conferences and a virtual Analyst Day focused o | Oct 22, 2026 |
| PROK | PRESS-RELEASE | neutral | 3/10 | ProKidney announced a virtual KOL event on October 27, 2026, featuring Dr. Katherine Tuttle to discuss new insights into | Oct 22, 2026 |
| RNXT | PRESS-RELEASE | neutral | 1/10 | RenovoRx, Inc. announced it will report its Q3 2026 results on November 5, 2026. | Oct 22, 2026 |
| HALO | PRESS-RELEASE | neutral | 1/10 | Halozyme Therapeutics, Inc. announced it will report its Q3 2026 results on November 5, 2026. | Oct 22, 2026 |
| VCEL | PRESS-RELEASE | neutral | 1/10 | Vericel Corporation announced it will report its Q3 2026 results on November 5, 2026. | Oct 22, 2026 |